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Introduction 
Preeclampsia is a life-threatening, pregnancy-associated disorder characterized by 
the rapid development of hypertension with renal dysfunction. While preeclampsia 
generally occurs later in pregnancy, early-onset preeclampsia (EOPE) can occur 
much earlier and is usually more devastating. Early-onset preeclampsia is also 
associated with an increased risk of maternal cardiovascular and metabolic disease 
in mothers later in life and neurocognitive dysfunction in their offspring. EOPE is 
strongly associated with abnormal placental development and fetal growth 
restriction during pregnancy. 
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Figure 1. The defining characteristics of preeclampsia, a pregnancy-associated disorder.
The placenta is a transient organ that is formed during pregnancy and is essential 
for embryonic survival. Hypoxia-inducible factor 1 alpha (Hif-1α) is a critical oxygen-
sensing transcription factor that has been implicated as a major regulator of 
trophoblast differentiation. Trophoblasts are cells that make up the fetal component 
of the placenta. Elevated Hif-1α has been linked to preeclampsia in humans. Our 
findings, in a newly developed mouse model, provide compelling evidence that Hif-
1α is a critical molecular mediator of placental development and indicates that 
prolonged expression of Hif-1α, exclusively in placental trophoblasts during 
pregnancy, causes maternal pathology and fetal growth restriction that is 
characteristic of EOPE. Although the association of Hif-1α and preeclampsia has 
been suggested, no study has quantified the levels of Hif-1α in humans in EOPE 
pregnancies. In addition, a comparison between early- and late-onset preeclampsia 
has not been made. Our study will establish the relationship between Hif-1α-positive 
placentas and the risk of future preeclamptic pregnancies as well as future maternal 
health. This includes the prevalence of preeclampsia in a subsequent pregnancy, 
long-term maternal cardiovascular health, and health issues in the offspring 
including neurocognitive impairments. These findings will determine if Hif-1α is a 
predictive marker for the risk of future adverse effects from preeclampsia in both 






Figure 2. Schematic of Hif-1α, hypoxia, and cell differentiation in the placenta. 
The Placenta 
The placenta is a maternofetal organ that is essential to the survival of a 
developing fetus. The placenta is composed of maternal tissue derived 
from the endometrium and fetal tissue from the chorionic sac. Functions of 
the placenta include facilitating blood flow, gas and nutrient exchange, 
waste elimination, hormone production and regulating the body 
temperature of the fetus. The placenta is also an immunoprivileged 
organ—when exposed to antigens, there is no inflammatory response. 
Maternal blood and fetal blood do not come in contact through the
placenta. 
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Figure 3. Full em t anatom ical placenta. 
Figure 4. Schematic of maternal and fetal arteries.
Risk Factors for Preeclampsia 
Antiphospholipid syndrome Chronic kidney disease 
Prior preeclampti c pregnancy Advanced maternal age (>40) 
Chronic hypert ensi on Fami ly hist ory of preec lampsi a 
Pregestational diabetes First pregnancy 
Multifetal pregnancy Age 
Obesity (BMI >30) Systemic lupus erythematosus 
In vitro fertilization (ART) Prior pregnancy with IUGR 
Procedure 
Pregnant women at Miami Valley Hospital have been approached for participation in
the study. Inclusion criteria include 1) age (18-40 years), 2) admission to labor and 
delivery, 3) diagnosis of preeclampsia, and 4) singleton pregnancy. Women who are 
obese or have diabetes have not been excluded but are noted to stratify the data. 
Upon delivery, a member of the team collects the placenta directly from the delivery 
room and within 15 minutes collects tissue samples. 1 cm3 of tissue is collected
from four quadrants of each the fetal and maternal faces of the placenta. 
Distinguish between the maternal and the fetal 
tissue. Remove fetal membrane. 
Collect samples from each quadrant of the fetal 
and maternal aspects of the placenta. 
Transfer tissue to liquid nitrogen, 
paraformaldehyde, and RNAlater. 
Analyze for Hif-1α using immunohistochemistry, 
Western blot, and ELISA. 
Figure 5. Schematic of collection process and four-quadrant system, fetal aspect up. 
Expectations
This project will allow for us to determine the percentage of early onset preeclamptic 
pregnancies which are Hif-1α positive. This information will then be applied to the
longitudinal portion of the study to allow for us to determine if Hif-1α can serve as a 
marker of preeclampsia in a subsequent pregnancy. In addition, other data such as 
preeclampsia with or without fetal growth restriction can be compared to the Hif-1α 
positive or negative placentas to determine other clinical findings that may be 
related to the presence of Hif-1α. We expect to answer are the following questions:
What is the prevalence of Hif-1α-positive EOPE pregnancies? 
Is Hif-1α a predictive marker of EOPE in subsequent pregnancies? 
Impact
If it is found that Hif-1α is a predictive marker of EOPE, women who are diagnosed 
with EOPE will could have their placentas tested for Hif-1α to determine the risk of 
EOPE in a subsequent pregnancy. In addition, this study will develop a longitudinal 
relationship between Hif-1α to subsequent pregnancies in the mother and their 
offspring. 
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